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Abstract
Objective: To study the association of long-term statin use and the risk of low-energy hip fractures in middle-aged and
elderly women.
Design: A register-based cohort study.
Setting: Finland.
Participants: Women aged 45–75 years initiating statin therapy between 1996 and 2001 with adherence to statins $80%
during the subsequent five years (n = 40 254), a respective cohort initiating hypertension drugs (n = 41 610), and women
randomly selected from the population (n = 62 585).
Main Outcome Measures: Incidence rate of and hazard ratio (HR) for low-energy hip fracture during the follow-up
extending up to 7 years after the 5-year exposure period.
Results: Altogether 199 low-energy hip fractures occurred during the 135 330 person-years (py) of follow-up in the statin
cohort, giving an incidence rate of 1.5 hip fractures per 1000 py. In the hypertension and the population cohorts, the rates
were 2.0 per 1000 py (312 fractures per 157 090 py) and 1.0 per 1000 py (212 fractures per 216 329 py), respectively.
Adjusting for a propensity score and individual variables strongly predicting the outcome, good adherence to statins for five
years was associated with a 29% decreased risk (HR 0.71; 95% CI 0.58–0.86) of a low-energy hip fracture in comparison with
adherent use of hypertension drugs. The association was of the same magnitude when comparing the statin users with the
population cohort, the HR being 0.69 (0.55–0.87). When women with poor (,40%), moderate (40 to 80%), and good
adherence ($80%) to statins were compared to those with good adherence to hypertension drugs ($80%) or to the
population cohort, the protective effect associated with statin use attenuated with the decreasing level of adherence.
Conclusions: 5-year exposure to statins is associated with a reduced risk of low-energy hip fracture in women aged 50–80
years without prior hospitalizations for fractures.
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Introduction
Impact of statins (hydroxymethylglutaryl-CoA reductase inhi-
bitors) on bone mineral density (BMD) has been debated since
simvastatin and lovastatin were discovered to increase bone
formation in animal experiments [1]. At the cellular level, there is
no doubt that statins can affect bone formation. By inhibiting
mevalonate pathway, statins decrease protein isoprenylation with
a subsequent activation of bone morphogenetic protein-2 which
contributes to osteoblast differentiation [1], [2]. Further support
for a biological effect of statins comes from a recent experimental
study which showed a drastic beneficial effect of locally
administered simvastatin on fracture healing [3].
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In clinical studies, observations on the effects of statins on bone
have been inconsistent, especially in postmenopausal women, the
most vulnerable population in terms of low energy fractures and
bone health. While one meta-analysis showed the effect of statin
use on various bone turn over markers in postmenopausal women
[4], another more recent meta-analysis found no effect of statin use
(1 year or less) on these markers in the same population [5]. A
modest positive effect of statin use on hip BMD in women was
found in two meta-analyses including various types of studies [4],
[6]. This finding could not be verified, however, when only
randomised trials were considered [5].
In theory, statins may have impact on both the BMD and micro
architecture and molecular composition of bone. Overall, the role
of BMD as a sole predictor of fractures has been questioned since
only a small proportion of patients with a low-energy fracture have
a decreased BMD [7]. Besides it, the micro architecture and
molecular composition of the bone may play a significant role
determining the bone quality [8].
Concerning hip fracture in women, a typical fracture in
osteoporosis, statin use was associated with a 25% reduced risk
(odds ratio [OR] 0.75; 95% CI 0.60–0.95) in a meta-analysis of
nine studies [4]. When considering any fracture in women, the OR
for a fracture associated with statin use was 0.80 in a meta-analysis
of 11 studies (0.66–0.96) [9]. The risk of any fracture in women
was analysed in two post-hoc studies of randomised trials on
cardiovascular end points [10], [11]. In the AFCAPS/TexCAPS
study, only one hip fracture occurred in each (lovastatin and
placebo) group [10]. In the LIPID study, data on the risk of hip
fracture in women was not presented [11] but the risk ratio for any
fracture favoring pravastatin was 0.78 (95% CI 0.54–1.14) [5],
[11].
We hypothesised that the exposure to statins should be at least
as long as bone renewal time in order to demonstrate an
association between statin use and such clinical outcomes as low-
energy osteoporotic fractures. As the exact duration of bone
renewal in hip in middle-aged or elderly women is not known, we
arbitrarily set the minimum exposure time to five years. In several
observational studies on statin use and risk of hip fracture in
women, the exposure periods have been considerably shorter than
five years [12], [13], [14]. Furthermore, in four prospective studies
with a similar follow-up time, the analyses were intention-to-treat,
the exposure being defined at baseline [15].
We performed a register-based study on the association of long-
term statin use with the risk of low-energy, potentially osteoporotic
fractures in middle-aged and elderly women. The primary aim was
to compare the incidence of low-energy hip fracture between
adherent users of statins and adherent users of antihypertensive
drugs. The comparator group was selected in order to control for
health seeking behaviour [16] and risk factors for cardiovascular
diseases and fractures unavailable in the registers. Secondly, the
incidence of low-energy hip fracture between statin users and
a randomly selected population cohort was compared.
Methods
Sources of Data
We used data from administrative health databases generated
through the universal health care and drug reimbursement systems
covering the 5.4 million residents of Finland. We identified
prescription records with the Prescription Register run since 1994
and managed by the Social Insurance Institution (SII) [17]. This
register contains records of prescription drug purchases re-
imbursed to residents in non-institutional settings. For each
purchase, the data include the dispensing date, the Anatomical
Therapeutic Chemical classification code presented by the WHO
[18], and the quantity dispensed. Permanent residents of the
country are eligible to drug reimbursement and are therefore
included in the Register, even if they did not get any
reimbursement. Patients staying in a public nursing home or
hospital without interruption for over 90 days are not eligible for
drug reimbursement, and their purchases are not registered. We
identified these patients from a separate SII register. For
identifying patients entitled to higher rates of reimbursement
because of certain severe, chronic conditions, such as coronary
artery disease, diabetes, rheumatoid arthritis, and organ trans-
plantations, we used the SII Special Reimbursement Register
introduced in 1964. To be eligible for special reimbursement,
a patient’s condition must meet explicit predefined criteria, and
a written certificate by a physician is required.
We identified low-energy hip fractures from the Finnish Care
Register, managed by the National Institute of Health and
Welfare. The register, covering all Finnish hospitals and all
hospitalizations regardless of the payer, includes individual
administrative data on primary and secondary discharge diagnoses
and the admission and discharge dates. The 10th revision of the
International Classification of Diseases (ICD-10) has been in use
since January 1, 1996. Properties of the fall (place and reason)
leading to a hospitalised injury can be registered but it is not
compulsory. The validity of the Finnish Care Register for hip
fractures has been tested comparing medical records, prospective
audit data, and the corresponding register data for 106 consecutive
patients hospitalised for hip fracture in one hospital in 1999–2000
[19]. The sensitivity of hip fracture diagnosis in the register varied
from 68.3% to 96.7%, depending on the specific site of the
fracture.
The data from the above databases were linked anonymously
using encrypted personal identifiers.
Cohorts and Exposure
Women aged 45–75 years by the end of the calendar year prior
to each selection year were eligible to be included in the source
population (Figure 1). Persons not considered eligible were those
entitled to special drug reimbursement due to organ transplanta-
tions, severe renal insufficiency, severe gastrointestinal disease
(mostly inflammatory bowel diseases), or Alzheimers disease
between 1996 and 2007. We excluded persons who died or were
institutionalised during the 5-year exposure period since the cohort
entry. From the hypertension cohort, we excluded persons who
had purchased antihypertensive drugs in the year preceding the
cohort entry. Next, we excluded from all cohorts those persons
who had had any fracture in the 365 days prior to the cohort entry
and those who had been hospitalised with any cancer diagnosis
(except for non-melanoma skin cancer), with a diagnosis of
pathological fracture, or with any fracture during the 5-year
exposure period. The follow-up for the cohorts started 5 years
since the cohort entry and ended when a person sustained a low-
energy hip fracture, met any of the exclusion criteria mentioned
above or on Dec 31, 2007 whichever came first (Figure 2). When
sampling the cohorts, we strove to similar distributions of the
cohort entry years.
Statin cohort. The statin cohort consisted of new users of
statins from 1996 to 2001. The cohort entry was defined as the
date of the first statin purchase. Those who had purchased statins
in 1994 or 1995 were excluded, and each person was considered as
an incident user only once. For the main analyses, the cohort was
restricted to those persons adherent to statins in the 5-year
exposure period. Adherence was defined as the Proportion of Days
Covered (PDC) $80% [20]. We used the one-tablet-a-day dosage
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assumption when calculating the PDC, i.e. a person had to have
purchased at least 1460 statin tablets during the 5 years (1825
days). Furthermore, at least 3 statin dispensations each year were
required. In Finland, a drug can be reimbursed for no longer than
3 months’ therapy per purchase. Statin use after the exposure
period was not considered.
For exposure-response relationship analyses, all statin initiators
were further divided into three groups of adherence in the 5-year
period: ,40%, 40–80%, and $80% plus at least 3 purchases each
year.
Hypertension cohort. The hypertension cohort consisted of
women who had not purchased drugs indicated in hypertension
(imidazoline receptor agonists, beta blockers, angiotensin-convert-
Figure 1. Flow diagram of the study cohorts. *Poor adherence=prescribed days covered ,80% in the 5-year exposure period and no more
than 2 purchased statin/hypertension drug prescription in each year. {Hypertension drugs =beta blockers, angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, calcium channel blockers.
doi:10.1371/journal.pone.0048095.g001
Figure 2. The study exposure and follow-up periods in relation to the calendar time. The figure is not to scale.
doi:10.1371/journal.pone.0048095.g002
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ing enzyme inhibitors or angiotensin receptor blockers, or calcium
channel blockers) any time since 1994 until their first antihyper-
tensive drug purchase between 1996 and 2001. The date of the
first purchase defined the cohort entry. As diuretics are indicated
also for several other conditions their use was not considered in the
cohort definition. We restricted the hypertension cohort to those
adherent to antihypertensive drugs or diuretics in the 5-year
exposure period using the same definition for the adherence as in
the statin cohort. Switching between drugs was considered as
continuing the therapy. Persons that purchased statins in 1996–
2006 could not be included in the hypertension cohort.
Population cohort. The population cohort consisted of
women randomly selected from the source population by using
the Prescription Register of the SII. Those who had no statin
purchases or who had no more than one statin purchase at any
point in 1995–2006 were included. The cohort entry date was set
at the 30th of June of the selection year.
Study End Points
We measured the occurrence of low-energy hip fractures over
up to 7 years of follow up (Figure 2). A hip fracture leads to
hospitalisation, and it is therefore comprehensively registered. A
low-energy fracture was defined as a discharge diagnosis of hip
fracture (ICD-10 codes S32.1, S32.3, S32.4, S72.0–S72.4, S72.7,
and S72.8) without any other fracture code and without road-
traffic accident codes as extrinsic factors. The codes of extrinsic
factors such as ‘‘fall on the same level’’ and ‘‘fall on the snow or
ice’’ were applied in the sensitivity analyses. The dates for death
and institutionalisation were provided by the SII.
Patient Characteristics
Patients’ age at the end of the year prior to the cohort entry,
hospital catchment area of the place of the residence, and the
calendar year of the cohort entry were recorded. We assessed
prescription drug use (insulin and other blood glucose lowering
drugs, imidazoline receptor agonists, diuretics, beta blockers,
calcium channel blockers, angiotensin-converting enzyme inhibi-
tors, angiotensin receptor blockers, hormone replacement therapy,
inhaled corticosteroids, bisphosphonates, calcitonin, thyroxin,
phenytoin, selective serotonin reuptake inhibitors) within the 365
days prior to the cohort entry and co-morbidities (coronary artery
disease, rheumatoid arthritis, cardiac insufficiency, cardiac ar-
rhythmias, epilepsy, parkinsonism), as captured by the SII
registers, any time before the cohort entry.
Statistical Analysis
We determined the incidence of hip fractures (per 1000 person-
years) among the cohorts. The hazard ratio (HR) was estimated
with Cox proportional-hazards regression. For confounder
adjustment, we used the propensity score (PS) method. The
propensity for adherence to statins was estimated separately in the
statin versus hypertension cohort analysis and in the statin versus
population cohort analysis by fitting a logistic regression model
including the characteristics measured at cohort entry (see above).
For the exposure-response analyses within the statin cohort,
separate PS models were constructed for propensity for good
versus moderate statin adherence and for good versus poor statin
adherence, respectively. For other exposure-response analyses,
several models were constructed modeling the PS for statin use in
each case. When comparing the statin users with the population,
the region of residence was excluded from the PS due to missing
data (12% of the population cohort). In addition to the exposure
group and the PS, the outcome models included those individual
confounding factors that were the strongest predictors of the
outcome (p,0.0001) [21]. When comparing the statin and
hypertension cohorts, age, coronary heart disease, rheumatoid
arthritis, use of antidiabetic drugs, and use of hormone re-
placement therapy were added in the model. In the statin versus
population analyses, these were further supplemented by the use of
diuretics, beta blockers, calcium channel blockers, and angioten-
sin-converting enzyme inhibitors or angiotensin receptor blockers.
The following exposure-response relationships were analysed by
comparing: 1) the incidence in different groups of adherence to
statins (,40%, 40–80%, $80% plus at least 3 purchases in each
year) with the incidence in the adherent users of antihypertensive
drugs and 2) with the incidence in the population cohort, and 3)
the incidence across adherence groups within the statin cohort.
For calculating P-values for trend, adherence to statins was defined
as a continuous variable obtaining values from 0 (no statin
exposure) to 3 (adherence to statins $80%).
In post hoc subgroup analyses, we first restricted the analyses to
hip fractures caused by falls on the same level, or falls on snow or
ice, by using the extrinsic factor codes provided in the Finnish
Care Register. Second, we included those with any fracture within
the 365 days prior to and during the exposure period to the study
population. Finally, we examined the effect of various modifica-
tions of the PS on the HRs. First, use of antipsychotics, anxiolytics,
hypnotics and sedatives, non-selective monoamine-reuptake in-
hibitors, monoamine oxidase type A inhibitors, or other anti-
depressants during the 365 days prior to the follow-up were added
to the PS model. Second, in a separate sensitivity analyses, each of
the following variables measured during the exposure period were
included in the PS: alcohol-related hospitalisation, use of bispho-
sphonates acting on mevalonate pathway (pamidronic acid,
alendronic acid, ibandronic acid, risedronic acid, zoledronic acid,
risedronic acid in combination preparation with calcium, or
risedronic acid with calcium and cholecalsiferol), and use of
medication indicated in diabetes or hypertension.
The study size was based on a priori estimation. During a 10-year
period among the population aged 50 years or older in Finland,
the mean number of the first records with hip fracture diagnosis
was 5564 per year in the early 2000’s [22]. In women, the number
was 4050 per year (Sund, personal communication) yielding an
incidence of 0.38% which we used as the incidence estimate for
the unexposed. A risk ratio of 0.75 [4] with the two-sided
significance level of 5% and 80% power was applied in
calculations conducted by the Epi-Info software (http://wwwn.
cdc.gov/epiinfo/). Aiming at the equal number of the exposed and
unexposed, approximately 57600 person years would be needed in
both groups.
We used SAS software (version 9.2; SAS Institute, Inc., Cary,
NC, USA) for statistical analyses.
Ethical considerations. The SII, the National Data Pro-
tection Agency, and the National Institute for Health and Welfare,
Helsinki, Finland approved the study protocol. There was no legal
requirement for an ethics committee approval because only de-
identified register data were used and the persons in the registers
were not contacted (the Finnish legislation at: http://www.finlex.
fi/fi/laki/ajantasa/1999/19990488). No written consent from
patients was required either.
Results
Of those 107 953 eligible women who initiated statin therapy in
1996–2001, 40 254 (37.3%) were included in the statin cohort
(Figure 1). In the hypertension cohort, 41 610 (34.1%) out of 122
114 were included. As there were no exclusions based on
adherence, 62 585 (90.2%) out of 69 705 eligible women were
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included in the population cohort. The cohorts differed in terms of
age and co-morbidity distributions (Table 1). In the hypertension
cohort, the distribution of the cohort entry year differed from that
in the other two cohorts. The statin cohort was the oldest, mean
age (SD) being 62.4 (7.5) years, with the highest prevalence of co-
morbidities and use of various drugs at cohort entry. The
population cohort was the youngest, 56.5 (8.7) years, with the
lowest prevalence of co-morbidities.
In the statin cohort, 199 women (0.50%) sustained hip fracture
during a mean of 3.36 years of follow-up, the respective figures in
the hypertension and population cohorts were 312 (0.75%, 3.78
years) and 212 (0.34%, 3.46 years) (Table 2). The incidence rate
was the highest in the hypertension cohort (2.0 hip fractures per
1000 person-years), followed by the statin (1.5) and the population
cohorts (1.0). Of the statin cohort, 1 397 (3.45%) persons died
during the follow-up. The respective figures in the hypertension
and population cohorts were 2 256 (5.42%) and 1 691 (2.70%).
When adjusting for the propensity score and individual
variables strongly predicting the outcome, good adherence to
statins for five years was associated with a 29% decreased risk (HR
0.71; 95% CI 0.58–0.86) of a low-energy hip fracture when
comparing with good adherence to antihypertensive drugs
(Table 3). The association was of the same magnitude when
comparing the statin users with the population cohort, HR being
0.69 (0.55–0.87).
Exposure-response Relationships
In order to analyse the exposure-response relationship, hip
fracture incidence rates in women with poor (,40%), moderate
(40–80%) and good ($80% plus at least 3 purchases per year)
Table 1. Selected characteristics of the persons in the study cohorts.
Statin
No (%)
(n =40254)
Hypertension
No (%)
(n =41610)
Population
No (%)
(n =62585)
Age at cohort entry
45–55 8428 (20.94) 15997 (38.45) 33682 (53.82)
56–65 16128 (40.07) 10655 (25.61) 16556 (26.45)
66–75 15698 (39.00) 14958 (35.95) 12347 (19.73)
Age, years, mean (SD) 62.4 (7.5) 60.2 (9.5) 56.5 (8.7)
Cohort entry
1996 4066 (10.10) 7694 (18.49) 6917 (11.05)
1997 5013 (12.45) 7018 (16.87) 8087 (12.92)
1998 5986 (14.87) 6758 (16.24) 9274 (14.82)
1999 7737 (19.22) 6650 (15.98) 11758 (18.79)
2000 9116 (22.65) 6650 (15.98) 13464 (21.51)
2001 8336 (20.71) 6840 (16.44) 13085 (20.91)
365 days prior to the cohort entry use of
Beta blockers 16299 (40.49) NA 6914 (11.05)
Hormone replacement therapy 12674 (31.49) 12172 (29.25) 15354 (24.53)
Diuretics 9067 (22.52) 7939 (19.08) 4596 (7.34)
Thiazides (alone or in combination preparations) 8887 (22.08) 6018 (14.46) 4457 (7.12)
Angiotensin-converting enzyme inhibitors or angiontensin
receptor blockers
8749 (21.73) NA 3766 (6.02)
Calcium channel blockers 7478 (18.58) NA 2893 (4.62)
Diabetes drugs 5111 (12.70) 1830 (4.40) 1115 (1.78)
Inhaled corticosteroids 2917 (7.25) 2514 (6.04) 3766 (6.02)
Bisphosphonates acting through mevalonate pathway* 468 (1.16) 386 (0.93) 352 (0.56)
Other bisphosphonates{ 91 (0.23) 89 (0.21) 85 (0.14)
Any time prior to the cohort entry evidence of{
Coronary artery disease 8072 (20.05) 1588 (3.82) 1295 (2.07)
Rheumatoid arthritis 1262 (3.14) 1797 (4.32) 1660 (2.65)
Cardiac insufficiency 1659 (4.12) 1589 (3.82) 689 (1.10)
Cardiac arrhythmias 923 (2.29) 687 (1.65) 452 (0.72)
Epilepsy 450 (1.12) 435 (1.05) 513 (0.82)
Parkinsonism 106 (0.26) 163 (0.39) 205 (0.33)
*Pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, risedronic acid in combination preparation with calcium, or risedronic acid with
calcium and cholecalsiferol.
{Etidronic acid, clodronic acid, tiludronic acid, or etidronic acid with calcium.
{As indicated in the Special Reimbursement Register of the Social Insurance Institution in Finland.
doi:10.1371/journal.pone.0048095.t001
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adherence to statins, respectively, were compared with those in
women with good adherence to the antihypertensive drugs. HRs
decreased from 0.89 (0.70–1.12) through 0.73 (0.58–0.91) to 0.71
(0.58–0.86) (P for trend 0.0002, Table 4). The respective
phenomenon was found in the statin versus population analyses;
HRs decreased from 0.87 (0.68–1.10) through 0.71 (0.51–1.00) to
0.69 (0.55–0.87) (P for trend 0.0005, Table 4).
Within the statin cohort, hip fracture risk tended to be lower in
the women with good adherence in comparison with the poor
adherence group (HR 0.82; 0.65–1.03) but no difference was
found between the moderate and good adherence groups (HR
1.01; 0.80–1.26) (Table 4).
Subgroup Analyses
The association between adherent use of statins and hip fracture
did not change when the outcome was defined as the fracture
caused by fall on the same level, or on the snow or ice (Table 5).
Using the above end point definition, the HR was 0.69 (0.56–0.86)
in the statin versus hypertension cohort comparison and 0.68
(0.52–0.88) in the statin versus population comparison.
Sensitivity Analyses
In sensitivity analyses, various variables measured during the
exposure period were added to the PS but these additions did not
affect the HRs (change in the estimate ,10%) in the outcome
models (Table 6).
Discussion
When women aged 50–80 years who had been adherent to
statins for 5 years were compared with women adherent to
antihypertensive drugs or with a cohort randomly selected from
the population, statin users were at a 30% decreased risk of hip
fracture over a mean of 3.57 years of follow-up. Furthermore,
when women with poor, moderate, and good adherence to statins
were compared to those with good adherence to antihypertensive
drugs or to the population cohort, the protective effect associated
with statin use increased with the increasing level of adherence.
Within the statin cohort, no difference in the risk of hip fractures
was found between women with moderate (40–80%) and good
adherence ($80% and at least three prescriptions per year) while
women with poor adherence (,40%) had a non-significant 20%
increase in risk compared with those having good adherence. The
finding, together with the results of other exposure-response
analyses, may indicate that even less intensive statin exposure may
be sufficient for improving bone health. When the analysis was
adjusted for both the PS and the use of drugs indicated in diabetes
or hypertension (including diuretics) during the follow-up the
results of the statin/hypertension analysis did not change but the
HR of the statin/population decreased to 0.64 (0.49–0.83)
(Table 6).The baseline characteristics of the women with poor
and good adherence differed; the mean age was higher and the
frequencies of cardiovascular medications and coronary artery
disease were higher in the women with good adherence (Table S2).
Consequently, better general health in the group with good
adherence cannot explain the results of the comparisons within the
statin group.
The results of our study with a long exposure duration are
concordant with the results from the post-hoc analyses of the
LIPID study in women [5] and with the results of previous
observational studies with heterogeneous exposure definitions in
women [4]. However, the associations found in our analyses are
Table 2. Patient follow-up, low-energy hip fracture, and incidence rates in the study cohorts.
Statin (n=40254)
Hypertension
(n =41610) Population (n =62585)
Follow-up time, years (mean, SD) 3.36 (1.64) 3.78 (1.86) 3.46 (1.66)
Events 199 312 212
Total follow-up time, person-years 135329.69 157090.10 216329.69
Incidence rate per 1000 person-years 1.5 2.0 1.0
SD= standard deviation.
doi:10.1371/journal.pone.0048095.t002
Table 3. Risk of low-energy hip fracture in adherent users of statins compared with adherent users of antihypertensive drugs and
with randomly selected population cohort.
Statin versus hypertension cohort
(n=81856*) HR (95% CI)
Statin versus population cohort
(n=102839) HR (95% CI)
Crude 0.75 (0.63–0.90)* 1.51 (1.24–1.83)
Adjusted for age and year of cohort entry 0.76 (0.63–0.91)* 0.93 (0.76–1.13)
Adjusted for propensity score and variables strongly
associated with
the outcome{,{
0.71 (0.58–0.86)* 0.69 (0.55–0.87)
*8 persons missing data on region of residence excluded.
HR =Hazard ratio.
{Age, coronary heart disease, rheumatoid arthritis, use of anti-diabetics, and hormone replacement therapy at cohort entry in the statin versus hypertension cohort
analyses.
{Variables mentioned above plus diuretics, beta blockers, calcium channel blockers, and angiotensinconverting enzyme inhibitors or angiotensin receptor blockers at
cohort entry in the statin versus population cohort analyses.
doi:10.1371/journal.pone.0048095.t003
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not as strong as those published more recently. In a Danish
population-based case-control study, 5-year statin adherence of at
least 58% (defined as good) was associated with a 43% reduction
(OR 0.57; 95% CI 0.39–0.84) in hip fracture risk in women [23].
In the same study, good statin adherence was associated with
a 89% reduction (OR 0.11; 95% CI 0.02–0.66) in hip fracture risk
in men aged 65 or younger. Furthermore, in a case-control study
from the USA, already a 3-month statin use was associated with
a 67% reduction (OR 0.23; 95% CI 0.09–0.57) in the hip fracture
risk in elderly women using hormone replacement therapy [14].
These estimates suggest that benefits of statin use would exceed the
achievements of conventional osteoporosis therapy [24] which
does not seem biologically plausible. Inadequate adjustment for
health seeking behavior and other types of residual confounding
may partly explain the above exceptional findings.
The proposed protective effect of statins in bone may be
explained by their biochemical effects on osteoblasts and
osteoclasts. By interfering in the mevalonate pathway, statins
suppress the synthesis of isoprenoids, such as farnesyl- and
geranylgeranyl pyrophosphate [2], which mimics the effect of
Table 4. Exposure-response relationships.
Crude
HR (95% CI)
Adjusted for age and year
of cohort entry HR (95% CI)
Adjusted for propensity score
and variables strongly
associated with the outcome HR
(95% CI)
Statin vs hypertension cohort
Poor adherence* to statins vs good
adherence to hypertension drugs (n = 62885)
0.76 (0.61–0.95) 0.89 (0.72–1.12) 0.89 (0.70–1.12)
Moderate adherence{ to statins vs good adherence to
hypertension drugs (n = 70091)
0.65 (0.53–0.80) 0.74 (0.60–0.91) 0.73 (0.58–0.91)
Good adherence{ to statins vs good
adherence to hypertension drugs (n = 81864)
0.75 (0.63–0.90)¥ 0.76 (0.63–0.91)¥ 0.71 (0.58–0.86) ¥
Statin vs population cohort
Poor adherence* to statins vs population (n = 83887) 1.49 (1.18–1.89) 1.06 (0.83–1.34) 0.87 (0.68–1.10)
Moderate adherence{ to statins vs population (n = 91072) 1.30 (1.04–1.63) 0.90 (0.72–1.12) 0.71 (0.51–1.00)
Good adherence{ to statins vs population (n = 102839) 1.51 (1.24–1.83)¥ 0.93 (0.76–1.13)¥ 0.69 (0.55–0.87) ¥
Within the statin cohort
Persons with good{ vs poor* adherence to statins
(n = 61566)
0.99 (0.79–1.26) 0.85 (0.67–1.08) 0.82 (0.65–1.03)
Persons with good{ vs moderate{
adherence to statins
(n = 68741)
1.15 (0.92–1.44) 1.03 (0.82–1.28) 1.01 (0.80–1.26)
Risk for low-energy hip fracture.
HR =Hazard ratio.
*Poor adherence = prescribed days statins covered ,40% of the 5-year exposure period.
{Moderate adherence =prescribed days statins covered $40% and ,80% of the 5-year exposure period.
{Good adherence = prescribed days statins/hypertension drugs covered $80% of the 5-year exposure period and at least 3 purchased statin/hypertension drug
prescriptions in each year.
¥Hazard ratios presented also in Table 3.
Persons missing data on region of residence excluded in all analyses.
doi:10.1371/journal.pone.0048095.t004
Table 5. Subgroup analysis.
Statin cohort versus
hypertension cohort HR
(95% CI)
Statin cohort versus population cohort
HR (95% CI)
Restricted to registered falls on the same level,
or falls on snow or ice
0.69 (0.56–0.86)*
(n = 81856, 413 events of the total 511)
0.68 (0.52–0.88)
(n = 102839, 327 events of the total 411)
Any fracture in the 365 days prior to the
exposure time examined in the propensity score and no
exclusion based on the fractures
0.68 (0.57–0.80)*
(n = 86259)
0.72 (0.59–0.88)
(n = 107552)
Any fracture in the 365 days prior to and during
the exposure time ignored (no exclusion
based on fractures)
0.67 (0.57–0.79)*
(n = 86259)
0.73 (0.60–0.89)
(n = 107552)
Risk for low-energy hip fractures.
*Persons missing data on region of residence excluded.
HR =Hazard ratio.
Hazard ratios were adjusted for propensity score and variables strongly associated with the outcome.
doi:10.1371/journal.pone.0048095.t005
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nitrogen-containing bisphosphonates inhibiting the same pathway
at the level of farnesyl pyrophosphate synthase [25]. Simvastatin
inhibits osteoclast differentiation [26], and both lipophilic [27] and
hydrophilic statins [28] induce osteoblast differentiation. In bone
of ovariectomized rats, simvastatin enhances the production of
osteogenic proteins [29] and induces oestrogen receptor-alpha
expression [30]. Since oestrogens slow down bone resorption and
increase bone mineral density [31], induction of oestrogen
receptor expression by statins, if functional also in postmenopausal
women, could attenuate the effect of decrease in oestrogen levels
or potentiate the effect of hormone replacement therapy on bone.
Existence of a specific pharmacological effect is further supported
by the finding that the fatty acid composition as such has no
significant role in bone health [32].
Strengths
The strengths of our study include the comprehensive
ascertainment of the outcome events, a long exposure period,
a priori power analysis, the adjustment for several confounders, the
observed exposure-response relationship, and the use of two
different comparison groups. We chose the adherent hypertension
cohort as a primary comparison group in order to control for
health seeking behaviour and, additionally, for some covariates,
such as body mass index (BMI), not available in the registers. In
postmenopausal women, total body fat, clinically considered in
BMI, is positively associated with the BMD [33], a predictor of
fracture [34]. High BMI, in turn, is associated both with
hypertension and hypercholesterolemia [35].
Limitations
The present study has weaknesses. Our definition of exposure,
adherence to statin therapy, is two-dimensional; we cannot
differentiate whether the associations or exposure-response
relationships are due to accumulating dose or due to adherent
behaviour, or both. Adherence to statin therapy may represent
health seeking behaviour consisting of numerous elements, in-
cluding use of preventive health services [36]. By choosing the
adherent users of antihypertensive drug as the main comparator
group we aimed to create groups similar in that respect. While
doing that, however, we may have introduced selection bias.
Women on antihypertensive drugs who initiated statin therapy
during 1996–2006 were selected to the statin cohort and excluded
from the hypertension cohort, the future statin initiation modifying
the selection. Consequently, frail women, women with several co-
morbidities, with less interest in health seeking, or with worse life-
time prognosis, i.e. those with high risk for hip fracture may have
been overrepresented in the hypertension cohort. In the statin
versus population comparison, we primarily hypothesised to find
a protective association due to health seeking behaviour of statin
users [36]. Specially, in this analysis, uncontrolled health seeking
behavior may have biased the effect estimates. We chose to study
the incidence rate of low-energy hip fracture as hip fracture has
been considered as an index fracture of osteoporosis. Hip
fractures, however, result from falls that are associated with
functional capacity, disability, and general health that we could
not control for. We could not control for use of vitamin D and
calcium supplements, dietary intake of them, physical activity,
genetic factors, or frailty. Even though we controlled for oestrogen
use, we did not take into account the duration or intensity of
exposure. We did not study use of non-statin lipid lowering drugs
as their consumption in Finland decreased during the study years
from 12.8% in 1996 to 1.9% in 2006 of the total lipid lowering
drug consumption measured as Defined Daily Doses/1000
inhabitants/day [37], [38].
Implications
Hip fracture can be considered as a burden to health care
systems worldwide, although the overall rate of hip fractures varies
across countries due to both genetic and environmental factors
[39]. Contemporary pharmacotherapy, such as bisphosphonates,
is rather ineffective in prevention of low-energy, osteoporotic
fractures [40], [41], [42]. For example, the NNT for hip fracture
prevention over 3 years in an osteoporotic subset of the population
ranged from 48 (strontium ranelate) to 91 (bisphosphonates) [43].
Our results can be translated into a naive´ number needed to treat
(NNT) [44]; 628 postmenopausal women without prior hospita-
lisations for fractures need to use statins adherently for at least
5 years in order to prevent one future low-energy hip fracture over
Table 6. Sensitivity analyses.
Statin cohort versus hypertension
cohort n=81864* HR (95% CI)
Statin cohort versus population
Cohort n =102839 HR (95% CI)
Use of antipsychotics, anxiolytics, hypnotics and sedatives,
non-selective monoamine-reuptake inhibitors,
monoamine oxidase type A inhibitors, or other antidepressants
during the 365 days prior to the follow-up added
0.70 (0.58–0.85) 0.68 (0.53–0.85)
Alcohol-related hospitalisation during the exposure
period added
0.71 (0.58–0.86) 0.69 (0.54–0.88)
Use of bisphosphonates (mevalonate pathway){ during
exposure period added
0.71 (0.58–0.86) 0.69 (0.54–0.87)
Use of medication indicated in diabetes or hypertension{
during the exposure period added
0.71 (0.58–0.86) 0.64 (0.49–0.83)
Risk for low-energy hip fracture. Various modifications in the propensity score examined.
HR =Hazard ratio.
Hazard ratios were adjusted for propensity score and variables strongly associated with the outcome.
*Persons missing data on region of residence excluded.
{Pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, risedronic acid in combination preparation with calcium, or risedronic acid with
calcium and cholecalsiferol.
{Insulin and other blood glucose lowering drugs, diuretics, beta blockers, calcium channel blockers or angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers.
Distribution of the variables used in the propensity score examinations are presented in the Table S1.
doi:10.1371/journal.pone.0048095.t006
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3 years of follow-up. The respective NNT for 5 years of follow-up
is 346. These estimates apply to a female population with
cardiovascular risk factors (but without data on BMD), i.e. women
using medication for hypercholesterolemia or for hypertension. In
further studies, impact of time-varying confounding factors and
the impact of various exposure durations on fracture risk are worth
exploring. Especially, the cumulative dose may be relevant as in
animal studies the doses have been ten times that used in routine
clinical practice [1].
Conclusions
In conclusion, our large population-based study suggests that
long-term exposure to statins is associated with a reduced risk of
low-energy hip fracture in women aged 50–80 years without prior
hospitalised fractures. Although the absolute benefit is small, some
extra benefit in bone health may be achieved when statins are used
for their main indication.
Supporting Information
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(PDF)
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(PDF)
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